Related Experiment Video
Updated: May 29, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
The HIV/HCV-coinfected patient and new treatment options
Marie-Louise C Vachon1, Douglas T Dieterich
1Division of Infectious Diseases, Mount Sinai School of Medicine, New York, NY 10029, USA.
Abstract:
Hepatitis C (HCV) treatment is on the cusp of change with the approval of the first direct-acting antivirals: telaprevir and boceprevir. Drug-drug interactions with HIV antiretrovirals, increased toxicity, and rapid selection of HCV-resistant mutants are among the treatment complexities expected in this difficult-to-treat population. Until the current standard of care changes, focus should be on strategies to optimize management of HIV/HCV-coinfected patients with currently available options. This article reviews the latest predictive factors of response to HCV treatment with the current standard of care in HIV-coinfected patients, and new treatment options.
Related Concept Videos
Retrovirus Life Cycles
Hepatitis
Viral Hepatitis I: Introduction
Treatment Resistent Cancers
Cryptococcal Meningitis
Treatment Resistant Cancers

